NCT06290141: An ongoing trial by Sanofi
This trial is ongoing. It must report results 2 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06290141 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 21, 2024 |
| Completion date | July 9, 2027 |
| Required reporting date | July 8, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 14, 2025 |
| Days late | None |